Explain the mechanism of acute respiratory distress syndrome

Reading File

Finding Sources

Searching PubMed

"acute respiratory distress syndrome"[MeSH Terms] AND pathogenesis

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

I now have all the material needed for a thorough, well-sourced answer. Here is the complete explanation:

Mechanism of Acute Respiratory Distress Syndrome (ARDS)

ARDS is a syndrome of non-cardiogenic pulmonary edema caused by diffuse alveolar damage (DAD) from an overwhelming, dysregulated inflammatory response. It follows the Berlin definition: bilateral infiltrates on imaging, PaO2/FiO2 ratio <300 mmHg, onset within 7 days of a known insult, and edema not fully explained by cardiac failure or fluid overload. - Sabiston Textbook of Surgery, p. 940

1. Precipitating Causes (Direct vs. Indirect Lung Injury)

Direct (pulmonary)	Indirect (extrapulmonary)
Pneumonia (most common)	Sepsis
Aspiration of gastric contents	Major trauma / hemorrhage
Inhalation injury	Severe pancreatitis
Pulmonary contusion	Massive transfusion (TRALI)
Near-drowning	Burns

The common endpoint across all these triggers is excessive and dysregulated inflammation at the alveolar-capillary interface. - Murray & Nadel's Textbook of Respiratory Medicine, p. 3144

2. Phases of ARDS

Time course diagram showing the three overlapping phases of ARDS: exudative (days 0-7), proliferative (days 7-14), and fibrotic (day 21+)

Figure 312-1 from Harrison's Principles of Internal Medicine, 22E: Time course of ARDS phases.

Phase 1: Exudative Phase (Days 0-7)

This is the acute inflammatory phase and is the mechanistic core of ARDS.

Step 1 - Initial insult and pattern recognition Microbial products (in sepsis/pneumonia) or tissue damage signals are recognized by resident alveolar macrophages and epithelial cells via pattern-recognition receptors (e.g., Toll-like receptors). This triggers release of pro-inflammatory cytokines - TNF-α, IL-1β, IL-6, IL-8 - and lipid mediators such as leukotriene B2. - Harrison's, p. 2652

Step 2 - Neutrophil sequestration and transmigration One of the earliest manifestations (preceding hypoxemia) is transient leukopenia from neutrophil sequestration in the pulmonary microvasculature. Pulmonary capillaries are physically narrower than neutrophil diameter, forcing them to deform during transit. Activated neutrophils become "stiff" due to actin cytoskeletal rearrangement and cannot negotiate narrow capillary segments, causing trapping. IL-8 and other chemoattractants then drive their transmigration across the alveolar-capillary membrane into the interstitium and alveoli. - Murray & Nadel, p. 3147

Step 3 - Neutrophil-mediated tissue destruction

Diagram of PMN (neutrophil) transmigration across the alveolar-capillary membrane, releasing elastase, proteases, ROS, cytokines, and NETs into both the endothelial and epithelial surfaces

Figure 134.3 from Murray & Nadel: Neutrophil-mediated alveolar injury in ARDS.

During excessive and dysregulated inflammation, activated neutrophils release their microbicidal arsenal into the extracellular space:

Neutrophil elastase - disrupts intercellular tight junctions and kills endothelial and epithelial cells; levels in bronchoalveolar lavage (BAL) fluid correlate with injury severity
Matrix metalloproteinases (MMPs) - derived from both neutrophils and macrophages, degrade junctional proteins in endothelia and epithelia
Reactive oxygen species (ROS) - oxidative injury to cell membranes and surfactant
Cationic peptides (defensins) and other serine proteases - further extracellular matrix destruction
Neutrophil extracellular traps (NETs) - chromatin-based webs that trap pathogens but also amplify sterile inflammation
Murray & Nadel, pp. 187, 3147

Step 4 - Alveolar-capillary barrier breakdown Injury to both the type I alveolar epithelial cells (95% of the alveolar surface) and the microvascular endothelium destroys the normally tight alveolar barrier. The dual-sided injury is the key event:

Loss of endothelial barrier integrity allows plasma proteins and fluid to leak from the capillary into the interstitium
Loss of epithelial barrier integrity allows this protein-rich fluid to flood the alveolar space
Impaired alveolar fluid clearance (loss of ion transport via Na/K-ATPase on type II pneumocytes) prevents removal of edema fluid
Murray & Nadel, p. 3146; Harrison's, p. 2652

Step 5 - Surfactant dysfunction Type II pneumocytes are injured or killed, reducing synthesis and secretion of surfactant. Additionally, phospholipase A2 (from inflammatory cells and, in pancreatitis, from the pancreas itself) enzymatically degrades surfactant. Plasma proteins leaking into the alveolus further inhibit surfactant function. This causes:

Increased alveolar surface tension
Alveolar collapse (atelectasis), particularly in dependent lung regions
Decreased lung compliance
Murray & Nadel, pp. 3146-3147; Murray & Nadel (pancreatitis chapter), p. 2961

Step 6 - Hyaline membrane formation Condensed plasma proteins aggregate with cellular debris and dysfunctional surfactant to form hyaline membrane whorls lining denuded alveolar surfaces - the pathologic hallmark of diffuse alveolar damage. - Harrison's, p. 2652

Step 7 - Vascular injury and pulmonary hypertension Simultaneously, pulmonary vascular injury occurs with:

Microthrombi formation and fibrocellular proliferation obliterating small vessels
Loss of ventilated alveoli increases intrapulmonary shunting → refractory hypoxemia
Microvascular occlusion reduces blood flow to still-ventilated alveoli → increased dead space and hypercapnia
Together these mechanisms cause pulmonary hypertension and increase right heart afterload
Harrison's, p. 2654

Phase 2: Proliferative Phase (Days 7-14)

Neutrophil influx decreases; monocytes/macrophages become the dominant inflammatory cell
Hyaline membranes begin to be reorganized
Type II pneumocytes (the progenitor cell of the alveolar epithelium) proliferate to repopulate denuded surfaces
Early interstitial inflammation and fibrosis begins; elevated N-terminal procollagen peptide III (a marker of collagen synthesis) is detectable in BAL fluid as early as 24 hours after onset - indicating that fibroproliferation may start simultaneously with the acute injury, not after it
Pulmonary edema diminishes
Most patients who recover do so during this phase
Murray & Nadel, p. 3145; Harrison's, p. 2657

Phase 3: Fibrotic Phase (Day 21+)

Occurs in a subset of patients with persistent ARDS (>2 weeks)
Obliteration of pulmonary capillaries, deposition of interstitial and alveolar collagen
Bullae formation, cystic changes
Progressive respiratory failure from fibrosis, not edema
Carries a substantially worse prognosis
Murray & Nadel, pp. 3074-3075; Harrison's, Figure 312-1

3. Pathophysiologic Consequences

Mechanism	Consequence
Flooded, collapsed alveoli (shunt)	Refractory hypoxemia (PaO2 does not respond to supplemental O2)
Increased alveolar dead space	Hypercapnia, increased work of breathing
Reduced surfactant, edematous lung	Decreased compliance, small functional residual capacity
Pulmonary vascular obliteration	Pulmonary hypertension, right heart strain
Dependent atelectasis	Heterogeneous injury - "baby lung" physiology

The heavy, edematous ARDS lung behaves like a sponge: lesions are gravity-dependent, with a fluid-filled/consolidated dependent zone and a relatively spared non-dependent zone - this is the basis of prone positioning as therapy. - Goldman-Cecil Medicine, p. 1067

4. Why ARDS Can Occur Without Neutrophils

Importantly, ARDS can develop in profoundly neutropenic patients, confirming that neutrophils, while central, are not the only effectors. Monocytes, macrophages, platelets, complement activation, coagulation cascades, and endothelial cell apoptosis all contribute independently. - Murray & Nadel, p. 187

5. Summary Diagram of Pathogenesis

Precipitating insult (pulmonary or systemic)
           ↓
Alveolar macrophage + epithelial activation
           ↓
Cytokines (TNF-α, IL-1β, IL-6, IL-8), LTB2
           ↓
Neutrophil sequestration → transmigration
           ↓
Release of elastase, MMPs, ROS, NETs, defensins
           ↓
Type I pneumocyte + endothelial cell death
           ↓
Alveolar-capillary barrier breakdown
           ↓
Protein-rich edema floods alveoli → hyaline membranes
Surfactant dysfunction → alveolar collapse
Microvascular thrombosis → pulmonary hypertension
           ↓
Intrapulmonary shunt + dead space
           ↓
Refractory hypoxemia + hypercapnia = ARDS

Key sources:

Murray & Nadel's Textbook of Respiratory Medicine, Chapter 134 (ARDS) and Chapter 8 (Lung Injury)
Harrison's Principles of Internal Medicine, 22E, Chapter 312
Goldman-Cecil Medicine, Chapter 91 (Mechanical Ventilation in ARDS)
Sabiston Textbook of Surgery, 11E

This is a shared conversation. Sign in to Orris to start your own chat.